Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Improvement of Outcome and Reduction of Toxicity in Elderly Patients with CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination with Vitamin D Substitution

NCT01478542 is registered in ClinicalTrials.gov with Universität des Saarlandes as lead sponsor.

NCT NCT01478542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01478542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Improvement of Outcome and Reduction of Toxicity in Elderly Patients with CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination with Vitamin D Substitution
Lead sponsor
Universität des Saarlandes
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
January 18, 2024
Enrollment
1,152 (actual)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

cd20+ aggressive b-cell lymphoma